Human Growth Hormone Market Report 2026

The human growth hormone market size has grown strongly in recent years. It will grow from $5.18 billion in 2025 to $5.68 billion in 2026 at a compound annual growth rate (CAGR) of 9.5%. The growth in the historic period can be attributed to increasing diagnosis of growth hormone deficiency, expansion of recombinant hormone production, growing awareness of pediatric growth disorders, rising availability of branded hgh therapies, long-standing clinical use of hormone replacement.

The human growth hormone market size is expected to see strong growth in the next few years. It will grow to $7.87 billion in 2030 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to increasing demand for long-acting growth hormone therapies, rising prevalence of adult growth hormone deficiency, growing focus on personalized endocrine treatments, expansion of specialty pharmacy distribution, increasing investment in hormone therapy research. Major trends in the forecast period include increasing demand for growth hormone deficiency treatments, rising adoption of long-acting growth hormone formulations, growing use of hgh in pediatric endocrinology, expansion of recombinant growth hormone therapies, increasing focus on patient adherence and convenient administration.

The growing aging population is expected to drive the growth of the human growth hormone (HGH) market in the coming years. An aging population refers to an increasing proportion of older individuals within a society, driven by longer life expectancy and declining birth rates. Advances in healthcare have contributed to longer lifespans, increasing the need for medical interventions to address age-related conditions. Human growth hormone is used by older adults under medical supervision to manage age-related muscle loss, decreased energy, and metabolic decline. For example, in January 2024, the Population Reference Bureau, a US-based non-profit organization, reported that the number of Americans aged 65 and older is projected to rise from 58 million in 2022 to 82 million by 2050, a 47% increase, raising their share of the total U.S. population from 17% to 23%. Consequently, the growth of the aging population is supporting the expansion of the HGH market.

Rising healthcare expenditure is also expected to propel the human growth hormone market. Healthcare expenditure encompasses the total spending on health services, products, and interventions aimed at maintaining and improving health. HGH therapy offers a way to potentially reduce long-term healthcare costs by addressing underlying health issues, enhancing recovery and quality of life, and mitigating the development of costly chronic conditions. For instance, in May 2023, the Office for National Statistics, a UK-based government department, reported that healthcare spending in the UK increased by 5.6% between 2022 and 2023, compared with 0.9% growth in 2022, reaching approximately $317.63 billion (£292 billion) in 2023. Therefore, rising healthcare expenditure is contributing to the growth of the HGH market.

Key companies in the human growth hormone market are focusing on drug development and regulatory approvals to enhance treatment options. Drug development is a complex process involving multiple stages to ensure the safety, efficacy, and quality of a new therapy before it reaches the market. For example, in June 2023, Pfizer Inc., a US-based biopharmaceutical company, and OPKO Health Inc., a US-based biopharmaceutical and diagnostics company, announced FDA approval of NGENLA (somatrogon-ghla). This long-acting growth hormone treatment provides a more convenient dosing regimen, improving patient adherence compared to daily injections. Children with growth hormone deficiency can now reduce injection frequency from daily to once weekly. The FDA approval was supported by a Phase 3 study demonstrating NGENLA’s non-inferiority to once-daily somatropin, with a comparable safety profile.

Major companies operating in the human growth hormone market are Pfizer Inc., Roche Holding AG, Novartis AG, Thermo Fisher Scientific Inc., Eli Lilly and Company, Novo Nordisk A/S, Merck KGaA, Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Ipsen Pharma, Ferring Holding SA, Endo International, Zydus Lifesciences Limited, Opko Health, LG Life Sciences, EMD Serono Inc., Wockhardt Ltd., JCR Pharmaceuticals Co. Ltd., Genentech Inc., SOFAR S.p.A., United Laboratories, Ascendis Pharma, Uni-Pharma S.A., Versartis Inc., Reliance Life Sciences, Anhui Anke Biotechnology (Group) Co. Ltd., Rani Therapeutics.

North America was the largest region in the human growth hormone market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human growth hormone market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the human growth hormone market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the human growth hormone market by increasing the cost of imported active pharmaceutical ingredients, recombinant manufacturing inputs, and specialized bioprocessing equipment. These effects are most pronounced for branded and recombinant hgh products and in regions such as North America and Europe that depend on global biopharmaceutical supply chains. Higher production costs may influence pricing and access; however, tariffs are also encouraging localized manufacturing, regional sourcing of raw materials, and investments in domestic biopharma capabilities, strengthening long-term supply security.

The human growth hormone market research report is one of a series of new reports that provides human growth hormone market statistics, including human growth hormone industry global market size, regional shares, competitors with a human growth hormone market share, detailed human growth hormone market segments, market trends and opportunities, and any further data you may need to thrive in the human growth hormone industry. This human growth hormone market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Human growth hormone (HGH) is a peptide hormone naturally secreted by the pituitary gland that plays a critical role in stimulating growth, promoting cell reproduction, and supporting tissue regeneration throughout the body. Medically, HGH is used to treat growth hormone deficiencies, support muscle development, and address age-related conditions such as muscle wasting and decreased bone density.

The main product forms of HGH are liquid and powder. Liquid formulations are typically provided as solutions or suspensions, ready for immediate use or injection. Key brands include Norditropin, Genotropin, Humatrope, Saizen, Omnitrope, Skytrofa, and others, administered through oral, intravenous, intramuscular, or subcutaneous routes. These products are distributed via hospital pharmacies, retail pharmacies, online pharmacies, and specialty pharmacies. HGH is used in a variety of therapeutic applications, including growth hormone (GH) deficiency, adult GH deficiency, pediatric GH deficiency, Turner syndrome, idiopathic short stature, Prader-Willi syndrome, small for gestational age, and other related conditions.

The human growth hormone market consists of sales of sustained-release formulations, combination therapies, biosimilar versions, long-acting formulations, pediatric-specific formulations, and personalized dosing regimens. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.